| You
are here: Home: BCU 5|2003: A
CME Audio Series and Activity
Breast Cancer Update: A CME Audio Series and Activity
STATEMENT OF NEED / TARGET AUDIENCE
Breast cancer is one of the most rapidly evolving fields in medical oncology.
Published results from a plethora of
ongoing clinical trials lead to the continuous emergence of new therapeutic
agents and changes in the
indications for existing treatments. In order to offer optimal patient care — including
the option of clinical trial
participation — the practicing medical oncologist must be well-informed
of these advances. To bridge the gap
between research and patient care, Breast Cancer Update uses one-on-one discussions
with leading oncology
investigators. By providing access to the latest research developments and
expert perspectives, this CME
program assists medical oncologists in the formulation of up-to-date clinical
management strategies.
GLOBAL LEARNING OBJECTIVES
Upon completion of this activity, participants should be able to:
- Critically evaluate the clinical implications of emerging clinical trial
data in breast cancer treatment.
- Describe and implement an algorithm for HER2 testing and treatment of
HER2-positive breast cancer
patients in your practice.
- Develop and explain a management strategy for treatment of ER-positive
breast cancer in the adjuvant,
neoadjuvant and metastatic settings.
- Develop and explain a management strategy for treatment of ER-negative
breast cancer in the adjuvant,
neoadjuvant and metastatic settings.
- Counsel ER-positive, postmenopausal patients about the risks and benefits
of aromatase inhibitors in the
adjuvant setting.
- Evaluate the emerging data on dose-dense chemotherapy and explain its
relevance to patients.
Issue 5, 2003, of Breast Cancer Update consists of discussions
with four research leaders on a variety of
important topics including chemotherapy and hormonal therapy
in combination with trastuzumab in the
metastatic setting, management of HER2-negative patients with
metastatic disease, dose-dense scheduling of
adjuvant therapy, use of adjuvant aromatase inhibitors, overcoming
resistance to endocrine therapy and ongoing
clinical trials in breast cancer.
SPECIFIC LEARNING OBJECTIVES FOR ISSUE 5
Upon completion of this activity, participants should be able
to:
- Evaluate novel data regarding dose-dense scheduling of chemotherapy and
the use of aromatase inhibitors
for adjuvant therapy.
- Learn potential strategies to overcome acquired resistance to endocrine
therapy.
- Develop awareness of the efficacy and tolerability data from clinical
trials of trastuzumab in combination with
platinum agents/chemotherapy and ongoing clinical trials
with trastuzumab in order to counsel appropriately
selected patients.
- Consider a spectrum of perspectives in the management strategies for
patients with ER-negative, HER2-
negative, metastatic breast cancer.
ACCREDITATION STATEMENT
NL Communications Inc is accredited by the Accreditation
Council for Continuing Medical Education to provide
continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
NL Communications Inc designates this educational
activity for a maximum of 3.25 category 1 credits
towards
the AMA Physician’s Recognition Award. Each
physician should claim only those credits that he/she
actually
spent on the activity.
|
